
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics Inc. is positioned for potential growth, as management anticipates an inflection in annual sales that could exceed the $500 million threshold, supported by a preliminary fourth-quarter 2025 net revenue of $259.2 million, reflecting a 9% increase from the previous quarter. The company's commitment to enhancing physician engagement is expected to bolster sales outcomes, while positive initial Phase 1/2 data from its FSHD and DM1 programs could introduce further upside potential for the stock. Furthermore, the favorable risk/benefit profile of the Elevidys product suggests an ability to effectively serve both ambulatory and non-ambulatory patients, enhancing future market penetration.
Bears say
Sarepta Therapeutics Inc. has reported a preliminary fourth-quarter 2025 net revenue of $110.4 million from its Elevidys product, falling short of consensus expectations and significantly below its own annual sales floor target of $500 million, indicating pressures on its sales projections. The company's revenue model appears increasingly vulnerable, as the reported sales represent only 29% of their peak revenue achieved in the fourth quarter of 2024, raising concerns over sustained demand and market positioning. Furthermore, Sarepta's reliance on third-party manufacturing and the early-stage development of most product candidates exacerbate its operational risks and uncertainty in the efficacy of its treatments, suggesting potential long-term challenges for the company's financial stability.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares